NCT00103285 · ADVERSE EVENTS

Adverse events

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2021-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Only eligible patients are included in the toxicity analysis.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Group 0 Induction Therapy All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \< 0.1% OR MRD \>= 0.1% and \< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study. cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT vincristine sulfate: Given IV	29 / 1306	790 / 1306	Not reported / Not reported
Group 1-SR-low ALL, Arm I-combination Chemotherapy Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	14 / 931	901 / 931	Not reported / Not reported
Group 1-SR-low ALL, Arm II-combination Chemotherapy Patients receive experimental consolidation therapy (vincristine sulfate, mercaptopurine, MTX, leucovorin calcium and pegaspargase), experimental interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine, MTX and pegaspargase), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	7 / 931	909 / 931	Not reported / Not reported
Group 2-SR-avg ALL, Arm I-combination Chemotherapy Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	4 / 501	487 / 501	Not reported / Not reported
Group 2-SR-avg ALL, Arm II-combination Chemotherapy Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and MTX. Patients with Down syndrome (DS) receive leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	3 / 509	500 / 509	Not reported / Not reported
Group 2-SR-avg ALL, Arm III-combination Chemotherapy Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and MTX. Patients with DS receive leucovorin calcium), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	0 / 246	237 / 246	Not reported / Not reported
Group 2-SR-avg ALL, Arm IV-combination Chemotherapy Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV	1 / 247	234 / 247	Not reported / Not reported
Group 3-SR-high ALL, Combination Chemotherapy Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine \& vincristine sulfate, pegaspargase, methotrexate. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (2 courses - vincristine sulfate, methotrexate and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (2 courses - vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, methotrexate. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT 3-dimensional conformal radiation therapy: Some patients undergo cranial radiotherapy cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine	12 / 638	629 / 638	Not reported / Not reported

Group identifiers: EG000: Group 0 Induction Therapy · EG001: Group 1-SR-low ALL, Arm I-combination Chemotherapy · EG002: Group 1-SR-low ALL, Arm II-combination Chemotherapy · EG003: Group 2-SR-avg ALL, Arm I-combination Chemotherapy · EG004: Group 2-SR-avg ALL, Arm II-combination Chemotherapy · EG005: Group 2-SR-avg ALL, Arm III-combination Chemotherapy · EG006: Group 2-SR-avg ALL, Arm IV-combination Chemotherapy · EG007: Group 3-SR-high ALL, Combination Chemotherapy

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Anemia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
1306
num Events
3
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Disseminated intravascular coagulation
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Febrile neutropenia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Hemolysis
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cardiac arrest
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Myocardial infarction
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Abdominal pain
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Ascites
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cecal hemorrhage
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Colitis
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Colonic perforation
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
1
num At Risk
931
num Events
1
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Diarrhea

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
86
num At Risk
1306
num Events
88
group Id
EG001
num Affected
258
num At Risk
931
num Events
438
group Id
EG002
num Affected
232
num At Risk
931
num Events
356
group Id
EG003
num Affected
119
num At Risk
501
num Events
183
group Id
EG004
num Affected
127
num At Risk
509
num Events
213
group Id
EG005
num Affected
55
num At Risk
246
num Events
113
group Id
EG006
num Affected
90
num At Risk
247
num Events
150
group Id
EG007
num Affected
213
num At Risk
638
num Events
466
term
Anemia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
8
num At Risk
931
num Events
16
group Id
EG002
num Affected
6
num At Risk
931
num Events
8
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
4
num At Risk
509
num Events
5
group Id
EG005
num Affected
2
num At Risk
246
num Events
2
group Id
EG006
num Affected
1
num At Risk
247
num Events
1
group Id
EG007
num Affected
9
num At Risk
638
num Events
9
term
Blood and lymphatic system disorders - Other, specify
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
1
num At Risk
246
num Events
2
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Bone marrow hypocellular
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
6
num At Risk
931
num Events
7
group Id
EG002
num Affected
2
num At Risk
931
num Events
2
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
2
num At Risk
638
num Events
2
term
Disseminated intravascular coagulation
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
130
num At Risk
1306
num Events
131
group Id
EG001
num Affected
531
num At Risk
931
num Events
1045
group Id
EG002
num Affected
555
num At Risk
931
num Events
1045
group Id
EG003
num Affected
272
num At Risk
501
num Events
513
group Id
EG004
num Affected
330
num At Risk
509
num Events
733
group Id
EG005
num Affected
144
num At Risk
246
num Events
259
group Id
EG006
num Affected
150
num At Risk
247
num Events
316
group Id
EG007
num Affected
475
num At Risk
638
num Events
1260
term
Febrile neutropenia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
6
num At Risk
931
num Events
6
group Id
EG002
num Affected
3
num At Risk
931
num Events
3
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Hemolysis
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Hemolytic uremic syndrome
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Leukocytosis
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
1
num At Risk
509
num Events
1
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Spleen disorder
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cardiac arrest
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
1306
num Events
3
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
1
num At Risk
931
num Events
1
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
1
num At Risk
246
num Events
1
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
2
num At Risk
638
num Events
2
term
Cardiac disorders - Other, specify
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Conduction disorder

Complete source fields

description

Only eligible patients are included in the toxicity analysis.

event Groups

description
All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \< 0.1% OR MRD \>= 0.1% and \< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study. cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT vincristine sulfate: Given IV
id
EG000
other Num Affected
790
other Num At Risk
1306
serious Num Affected
29
serious Num At Risk
1306
title
Group 0 Induction Therapy
description
Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG001
other Num Affected
901
other Num At Risk
931
serious Num Affected
14
serious Num At Risk
931
title
Group 1-SR-low ALL, Arm I-combination Chemotherapy
description
Patients receive experimental consolidation therapy (vincristine sulfate, mercaptopurine, MTX, leucovorin calcium and pegaspargase), experimental interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine, MTX and pegaspargase), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG002
other Num Affected
909
other Num At Risk
931
serious Num Affected
7
serious Num At Risk
931
title
Group 1-SR-low ALL, Arm II-combination Chemotherapy
description
Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG003
other Num Affected
487
other Num At Risk
501
serious Num Affected
4
serious Num At Risk
501
title
Group 2-SR-avg ALL, Arm I-combination Chemotherapy
description
Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and MTX. Patients with Down syndrome (DS) receive leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG004
other Num Affected
500
other Num At Risk
509
serious Num Affected
3
serious Num At Risk
509
title
Group 2-SR-avg ALL, Arm II-combination Chemotherapy
description
Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and MTX. Patients with DS receive leucovorin calcium), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG005
other Num Affected
237
other Num At Risk
246
serious Num Affected
0
serious Num At Risk
246
title
Group 2-SR-avg ALL, Arm III-combination Chemotherapy
description
Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine: Given PO cyclophosphamide: Given IV thioguanine: Given PO vincristine sulfate: Given IV
id
EG006
other Num Affected
234
other Num At Risk
247
serious Num Affected
1
serious Num At Risk
247
title
Group 2-SR-avg ALL, Arm IV-combination Chemotherapy
description
Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine \& vincristine sulfate, pegaspargase, methotrexate. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (2 courses - vincristine sulfate, methotrexate and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (2 courses - vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, methotrexate. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years. doxorubicin hydrochloride: Given IV or IT 3-dimensional conformal radiation therapy: Some patients undergo cranial radiotherapy cytarabine: Given IV or SC dexamethasone: Given IV or PO pegaspargase: Given IM methotrexate: Given IM or IT leucovorin calcium: Given PO mercaptopurine
id
EG007
other Num Affected
629
other Num At Risk
638
serious Num Affected
12
serious Num At Risk
638
title
Group 3-SR-high ALL, Combination Chemotherapy

frequency Threshold

other Events

organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
86
num At Risk
1306
num Events
88
group Id
EG001
num Affected
258
num At Risk
931
num Events
438
group Id
EG002
num Affected
232
num At Risk
931
num Events
356
group Id
EG003
num Affected
119
num At Risk
501
num Events
183
group Id
EG004
num Affected
127
num At Risk
509
num Events
213
group Id
EG005
num Affected
55
num At Risk
246
num Events
113
group Id
EG006
num Affected
90
num At Risk
247
num Events
150
group Id
EG007
num Affected
213
num At Risk
638
num Events
466
term
Anemia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
8
num At Risk
931
num Events
16
group Id
EG002
num Affected
6
num At Risk
931
num Events
8
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
4
num At Risk
509
num Events
5
group Id
EG005
num Affected
2
num At Risk
246
num Events
2
group Id
EG006
num Affected
1
num At Risk
247
num Events
1
group Id
EG007
num Affected
9
num At Risk
638
num Events
9
term
Blood and lymphatic system disorders - Other, specify
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
1
num At Risk
246
num Events
2
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Bone marrow hypocellular
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
6
num At Risk
931
num Events
7
group Id
EG002
num Affected
2
num At Risk
931
num Events
2
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
2
num At Risk
638
num Events
2
term
Disseminated intravascular coagulation
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
130
num At Risk
1306
num Events
131
group Id
EG001
num Affected
531
num At Risk
931
num Events
1045
group Id
EG002
num Affected
555
num At Risk
931
num Events
1045
group Id
EG003
num Affected
272
num At Risk
501
num Events
513
group Id
EG004
num Affected
330
num At Risk
509
num Events
733
group Id
EG005
num Affected
144
num At Risk
246
num Events
259
group Id
EG006
num Affected
150
num At Risk
247
num Events
316
group Id
EG007
num Affected
475
num At Risk
638
num Events
1260
term
Febrile neutropenia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
6
num At Risk
931
num Events
6
group Id
EG002
num Affected
3
num At Risk
931
num Events
3
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Hemolysis
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Hemolytic uremic syndrome
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
1
num At Risk
501
num Events
1
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Leukocytosis
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
1
num At Risk
509
num Events
1
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Spleen disorder
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cardiac arrest
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
1306
num Events
3
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
1
num At Risk
931
num Events
1
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
1
num At Risk
246
num Events
1
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
2
num At Risk
638
num Events
2
term
Cardiac disorders - Other, specify
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Conduction disorder

serious Events

organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Anemia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
3
num At Risk
1306
num Events
3
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Disseminated intravascular coagulation
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
2
num At Risk
931
num Events
2
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Febrile neutropenia
organ System
Blood and lymphatic system disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Hemolysis
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
2
num At Risk
1306
num Events
2
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cardiac arrest
organ System
Cardiac disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Myocardial infarction
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
1
num At Risk
931
num Events
1
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Abdominal pain
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Ascites
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Cecal hemorrhage
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Colitis
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
0
num At Risk
1306
num Events
0
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
0
num At Risk
931
num Events
0
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
1
num At Risk
638
num Events
1
term
Colonic perforation
organ System
Gastrointestinal disorders
source Vocabulary
CTCv4
stats
group Id
EG000
num Affected
1
num At Risk
1306
num Events
1
group Id
EG001
num Affected
0
num At Risk
931
num Events
0
group Id
EG002
num Affected
1
num At Risk
931
num Events
1
group Id
EG003
num Affected
0
num At Risk
501
num Events
0
group Id
EG004
num Affected
0
num At Risk
509
num Events
0
group Id
EG005
num Affected
0
num At Risk
246
num Events
0
group Id
EG006
num Affected
0
num At Risk
247
num Events
0
group Id
EG007
num Affected
0
num At Risk
638
num Events
0
term
Diarrhea

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice